Glenn Noronha, PhD, has joined PYC Therapeutics (ASX:PYC) as chief development officer to oversee the company’s translational clinical development, regulatory, manufacturing and preclinical development activities as it advances its pipeline of multiple drug candidates, which is initially focused on inherited ocular diseases.
Dr. Noronha brings more than 20 years of progressive leadership and research experience to PYC across both small and large biotechnology and pharmaceutical companies, with deep expertise in development of ophthalmology drug candidates, through his positions at BridgeBio Pharma, Clearside Biomedical and Alcon, formerly the ophthalmology subsidiary of Novartis.
Dr. Noronha has been involved with eight IND applications and three NDAs with the FDA.
In a statement, Sahm Nasseri, U.S. CEO of PYC, said Dr. Noronha’s appointment strengthens the U.S. executive leadership team by adding significant operational expertise. “He will play an essential role in transforming PYC into a clinical-stage company as we progress our pipeline development programs, including VP-001, our lead candidate for retinitis pigmentosa type 11.”
Dr. Noronha said this is a pivotal time for PYC as it initially targets inherited ocular diseases, builds its presence in the U.S. and advances its pioneering RNA therapeutics pipeline toward clinical development.
“I have dedicated my career to developing therapies for ophthalmology patients with conditions where there is unmet or underserved need, and I am excited to collaborate with the dynamic PYC team that also prioritizes this goal,” he added.
